Our Work
Latham & Watkins Advises on Longboard Pharmaceuticals Pricing of Public Offering of Common Stock
February 8, 2023
San Diego capital markets team represented the underwriters in the offering by the clinical-stage biopharmaceutical company.
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, has announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its voting common stock at a price to the public of US$4.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be US$20 million.
Latham & Watkins LLP represented the underwriters in the offering with a San Diego capital markets team led by partners Matt Bush and Cheston Larson, with associates Peter Simon and Shelby Harrison.